SGLT2 inhibitors improve survival and renal outcomes in heart failure: Lancet Medha Baranwal16 Sept 2020 7:50 AM ISTFrance: Treatment with empagliflozin and dapagliflozin reduces all-cause mortality and improves renal outcomes in patients with heart failure with...
SGLT2 inhibitors reduce atrial fibrillation progression in Diabetes, finds study Medha Baranwal3 Sept 2020 11:00 AM ISTChina: The use of SGLT2 inhibitors in type 2 diabetes (T2D) patients may help in atrial fibrillation (AF)/atrial flutter (AFL) reduction,...
ESC update: Empagliflozin Cuts risk of Hospitalization, CV Mortality in HFrEF: EMPEROR Hina Zahid29 Aug 2020 11:45 AM ISTSophia Antipolis, France - Empagliflozin is second SGLT2 inhibitor after dapagliflozin to show a significant benefit in the treatment of reduced...
Empagliflozin add on to insulin premix effectively lowers blood sugar in diabetes: Study Medha Baranwal25 Aug 2020 7:09 PM ISTTaiwan: The addition of SGLT2 inhibitor empagliflozin versus linagliptin for 24 weeks to premixed insulin provides better blood sugar...
SGLT2 inhibitors may increase risk of genital mycotic infections, finds review Medha Baranwal22 Aug 2020 10:30 AM ISTUSA: Researchers have found in a review that the use of SGLT2 inhibitors increases the risk of mild genital mycotic infections (GMIs). Due to which...
No increased risk of Knee Amputations with SGLT2 Inhibitors, finds study Dr Satabdi Saha17 Aug 2020 2:26 PM ISTA recent study has reported no association between SGLT2 inhibitor use and incident below-knee amputations among patients with type 2 diabetes when...
Rosuvastatin coprescription with canagliflozin tied to Statin toxicity Hina Zahid4 Aug 2020 12:30 PM ISTResearchers have found in a case study that Coprescription of rosuvastatin and canagliflozin may lead to Statin toxicity.Physicians should be aware...
SGLT2 inhibitors triple DKA risk in type 2 diabetes patients, finds study Medha Baranwal30 July 2020 10:00 AM ISTCanada: The use of SGLT-2 inhibitors increases the risk for diabetic ketoacidosis (DKA) threefold in patients with type 2 diabetes (T2D), according to...
Ertugliflozin reduces hospitalization risk due to heart failure in diabetes Medha Baranwal25 Jun 2020 10:45 AM ISTDelhi: SGTL2 inhibitor ertugliflozin reduces heart failure hospitalization risk but does not confer a cardiovascular mortality benefit in...
Metformin and SGLT2 Inhibitor combo helps attain HbA1c of <8% in most Diabetics Dr.Niharika Harsha B18 Jun 2020 10:44 AM ISTComplex pathophysiology and multiple physiological factors play a key role in the onset and the progression of Diabetes Mellitus. Combination therapy...
SGLT2 inhibitors may protect diabetics against serious kidney problems Hina Zahid30 April 2020 12:30 PM ISTUse of sodium glucose cotransporter 2 (SGLT2) inhibitors to treat type 2 diabetes may help to lower the risk of serious kidney problems, finds a study...
